(Q28373212)

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059010-00010

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059010-00010

Photostability and biological activity of fluoroquinolones substituted at the 8 position after UV irradiation

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059010-00010

In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.

21 January 2018

1 reference

12 December 2020

Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group

1 reference

12 December 2020

Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect

1 reference

12 December 2020

Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone

1 reference

12 December 2020

Pharmacodynamics of fluoroquinolones

1 reference

12 December 2020

Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

1 reference

12 December 2020

Absolute bioavailability of moxifloxacin

1 reference

12 December 2020

In vitro activity of BAY 12-8039, a new fluoroquinolone

1 reference

12 December 2020

Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci

1 reference

12 December 2020

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

1 reference

12 December 2020

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

12 December 2020

Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group

1 reference

12 December 2020

Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model

1 reference

12 December 2020

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

12 December 2020

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

12 December 2020

Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines

1 reference

12 December 2020

Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers

1 reference

12 December 2020

Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.

1 reference

12 December 2020

The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.

1 reference

12 December 2020

In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.

1 reference

12 December 2020

The new fluoroquinolones: A critical review

1 reference

12 December 2020

Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells

1 reference

12 December 2020

Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests

1 reference

12 December 2020

Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America

1 reference

12 December 2020

Community-acquired pneumonia

1 reference

12 December 2020

Moxifloxacin in the therapy of experimental pneumococcal meningitis

1 reference

12 December 2020

Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae

1 reference

12 December 2020

Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections

1 reference

12 December 2020

Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae

1 reference

12 December 2020

In vitro activity of the new quinolone moxifloxacin (Bay 12-8039) against resistant gram-positive clinical isolates.

1 reference

12 December 2020

Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration

1 reference

12 December 2020

Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.

1 reference

12 December 2020

BAY 12-8039, a novel fluoroquinolone. Activity against important respiratory tract pathogens

1 reference

12 December 2020

Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin

1 reference

12 December 2020

Pharmacokinetics of gyrase inhibitors, Part 2: Renal and hepatic elimination pathways and drug interactions.

1 reference

12 December 2020

Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxa

1 reference

12 December 2020

Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

In vitro activity of Bay 12-8039, a new 8-methoxyquinolone

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

1 reference

12 December 2020

The role of antimicrobial therapy in acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract

1 reference

12 December 2020

Susceptibilities of Legionella spp. to newer antimicrobials in vitro

1 reference

12 December 2020

Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. The British Thoracic Society

1 reference

12 December 2020

Practical considerations and guidelines for the management of community-acquired pneumonia

1 reference

12 December 2020

Fluoroquinolones: interaction profile during enteral absorption.

1 reference

12 December 2020

Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro

1 reference

12 December 2020

Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits

1 reference

12 December 2020

Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents

1 reference

12 December 2020

Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

12 December 2020

Toxicity of quinolones

1 reference

12 December 2020

Management of chronic bronchitis and acute exacerbations of chronic bronchitis

1 reference

12 December 2020

Trends in bacterial resistance to fluoroquinolones

1 reference

12 December 2020

The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus

1 reference

12 December 2020

Penetration of moxifloxacin into peripheral compartments in humans.

1 reference

12 December 2020

Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics.

1 reference

12 December 2020

The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.

1 reference

12 December 2020

A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones'.

1 reference

12 December 2020

Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

1 reference

12 December 2020

Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.

1 reference

12 December 2020

A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group

1 reference

12 December 2020

High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

1 reference

12 December 2020

1 reference

12 December 2020

Bactericidal properties of moxifloxacin and post-antibiotic effect.

1 reference

12 December 2020

Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man

1 reference

12 December 2020

1 reference

12 December 2020